Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announce

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and pr

HWG Holdings LP acquired a new position in Natera, Inc. (NASDAQ: NTRA) in the undefined quarter, acc

Barclays analyst Luke Sergott maintains Natera (NASDAQ:NTRA) with a Overweight and raises the pri

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and pr

Citigroup analyst Albert Hu maintains Natera (NASDAQ:NTRA) with a Buy and raises the price target

Natera, Inc. (NASDAQ: NTRA - Get Free Report) reached a new 52-week high on Tuesday. The stock trade

[url="]Natera, Inc.[/url] (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, t

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and pr

Natera (NASDAQ:NTRA) has outperformed the market over the past 10 years by 29.68% on an annualized b

Trial will use Natera’s ultrasensitive MRD test, Signatera Genome with Phased and Structural Variant

BOSTON & AUSTIN, Texas--(BUSINESS WIRE)--Alliance Foundation Trials, LLC (AFT), a national leader in

Natera, Inc. (NASDAQ: NTRA - Get Free Report) CEO Steven Chapman sold 1,273 shares of the business's

What happened Natera, Inc. (NASDAQ: NTRA) insider Solomon Moshkevich sold 3,000 shares on 2026-10-01

Guggenheim analyst Subbu Nambi maintains Natera (NASDAQ:NTRA) with a Buy and raises the price tar

Strong performance across the healthtech sector over the past two quarters has sparked renewed marke

A look at the stocks that are owned by Cathie Wood's Ark Invest and Donald Trump.

Natera (NASDAQ:NTRA) has outperformed the market over the past 5 years by 17.64% on an annualized ba

On CNBC's “Halftime Report Final Trades,” Rob Sechan, CEO of NewEdge Wealth, picked Hewlett Packard

CNBC’s Final Trades: Rob Sechan picks Hewlett Packard, Kevin Simpson favors Natera, and Stephen Weis

RBC Capital analyst Dan Leonard maintains Natera (NASDAQ:NTRA) with a Outperform and raises the p

NTRA wins Japan PMDA approval for Signatera in muscle-invasive bladder cancer, supporting treatment

Natera, Inc. (NASDAQ: NTRA - Get Free Report) shares hit a new 52-week high during mid-day trading o

Louis says buy the AI dip

On CNBC's “Halftime Report Final Trades,” Bryn Talkington, managing partner of Requisite Capital Man

CNBC’s Final Trades featured Uber, Micron, Natera and Datadog, with analysts citing bullish views an

This approval supports the use of the Signatera test to guide adjuvant atezolizumab (Tecentriq®) tre

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and pr

Natera, Inc. (NTRA) Presents at 2026 Global Healthcare Conference Transcript

Natera, Inc. (NTRA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

The sale was executed under a pre-arranged Rule 10b5-1 plan amended in March 2026, leaving Chapman w

[url="]Natera, Inc.[/url] (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, t

UBS analyst Doug Schenkel maintains Natera (NASDAQ:NTRA) with a Buy and raises the price target f

Rothschild & Co analyst Jamie Clark initiates coverage on Natera (NASDAQ:NTRA) with a Buy rat

Natera (NASDAQ:NTRA) has outperformed the market over the past 10 years by 27.54% on an annualized b

Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today announced

Angiex is conducting a Phase I clinical trial of AGX101, an investigational TM4SF1-directed ND-ADC.

Natera (NASDAQ:NTRA) has outperformed the market over the past 10 years by 27.63% on an annualized b

Citigroup analyst Brendan Digan maintains Natera (NASDAQ:NTRA) with a Buy and raises the price ta

Piper Sandler analyst David Westenberg maintains Natera (NASDAQ:NTRA) with a Overweight and raise

Stephens & Co. analyst Mason Carrico maintains Natera (NASDAQ:NTRA) with a Overweight and rai

Guggenheim analyst Subbu Nambi maintains Natera (NASDAQ:NTRA) with a Buy and raises the price tar

Phase I trial in Germany will support treatment response monitoring for Kupando Therapeutics’ invest

TD Cowen analyst Dan Brennan maintains Natera (NASDAQ:NTRA) with a Buy and raises the price targe

Citigroup analyst Brendan Digan maintains Natera (NASDAQ:NTRA) with a Buy and raises the price ta

RBC Capital analyst Dan Leonard maintains Natera (NASDAQ:NTRA) with a Outperform and raises the p

U.S. stocks rose, Nasdaq Composite up 1%. Natera Inc (NTRA) shares jump 20.5% after strong Q2 result

Natera stock spikes as strong oncology demand drives record test volumes and a full-year revenue out

JP Morgan analyst Casey Woodring maintains Natera (NASDAQ:NTRA) with a Overweight and raises the

Wells Fargo analyst Evan Stampler maintains Natera (NASDAQ:NTRA) with a Equal-Weight and raises t